# US 2024/0342322 A1 · Netrin-1 detection, companion test and therapy based on radiations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0342322 A1
- Document ID: US20240342322A1
- Status: Published application
- Kind: A1
- Application number: 18/291,972
- Filed: 2022-07-26
- Published: 2024-10-17
- Earliest claimed: 2021-07-27
- Assignees: Netris Pharma; Centre National De La Recherche Scientifique; Institut National De La Sante Et De La Recherche Medical (Inserm); Universite Claude Bernard Lyon 1; Centre Leon Berard; Hospices Civils De Lyon
- Applicants: Netris Pharma; Centre national de la recherche scientifique; Institut National De La Sante Et De La Recherche Medical (Inserm); Université Claude Bernard Lyon 1; Centre Leon Berard; Hospices Civils De Lyon
- Inventors: Mathieu RICHAUD; Jennifer WISCHHUSEN; David NEVES; Patrick MEHLEN; David SARRUT; Benjamin GIBERT; David KRYZA
- Web page: https://patentgrep.com/patent/US20240342322A1

## CPC

- A61K 51/1021: {against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons}
- A61K 51/1018: {against material from animals or humans}
- A61K 51/1045: {against animal or human tumor cells or tumor cell determinants}
- A61K 51/1051: {the tumor cell being from breast, e.g. the antibody being herceptin}
- A61K 51/1093: {conjugates with carriers being antibodies}
- A61K 51/1096: {radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications}
- A61P 35/00: Antineoplastic agents
- C07K 16/22: against growth factors {; against growth regulators}
- A61K 2039/505: {comprising antibodies}
- A61K 2121/00: Preparations for use in therapy
- A61K 2123/00: Preparations for testing in vivo
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/54: F(ab')2
- C07K 2317/55: Fab or Fab'
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention is based on the finding that Netrin-(1) is retained in a stickier manner in the cell matrix at the cell periphery of the cancer cells, whereas Netrin-(1) is expressed in adults specifically in some tumors. It is also shown herein that Netrin-(1) is expressed very early during tumor formation. This makes Netrin-(1) an unexpected very specific target for imagery and/or targeted therapy. The present invention thus relates to compounds comprising an anti-Netrin-1 antibody, especially NP(137), a chelating moiety, optionally associated with a radioisotope, and their use either in imagery, diagnosis, especially companion diagnosis, or in targeted therapy. New diagnostic tests, which may be companion tests, and new cancer therapies, that may be combined to the companion test, are also proposed.

## Claims

### Claim at position 1

-17. (canceled)

### Claim 18

A compound comprising:
an anti-Netrin-1 antibody or antigen binding fragment thereof, and
a chelating moiety bound to said antibody or fragment.

### Claim 19 (depends on 18)

The compound of claim 18, wherein said chelating moiety is associated with a radioisotope.

### Claim 20 (depends on 18)

The compound of claim 18, wherein the antibody is a monoclonal antibody or an antigen-binding fragment thereof, comprising
a variable domain VH comprising:
a H-CDR1 having a sequence set forth as SEQ ID NO: 1;
a H-CDR2 having a sequence set forth as SEQ ID NO: 2;
a H-CDR3 having a sequence set forth as SEQ ID NO: 3;
a variable domain VL comprising:
a L-CDR1 having a sequence set forth as SEQ ID NO: 4;
a L-CDR2 having a sequence YAS;
a L-CDR3 having a sequence set forth as SEQ ID NO: 5;
or
a variable domain VH comprising:
a H-CDR1 having a sequence set forth as SEQ ID NO: 22;
a H-CDR2 having a sequence set forth as SEQ ID NO: 23;
a H-CDR3 having a sequence set forth as SEQ ID NO: 24;
a variable domain VL comprising:
a L-CDR1 having a sequence set forth as SEQ ID NO: 25;
a L-CDR2 having a sequence set forth as SEQ ID NO: 26;
a L-CDR3 having a sequence set forth as SEQ ID NO: 5.

### Claim 21 (depends on 18)

The compound of claim 18, wherein the antibody is a monoclonal antibody or an antigen-binding fragment thereof, wherein the antibody is a monoclonal antibody or an antigen-binding fragment thereof, comprising a pair of VH and VL sequences selected from the following pairs: SEQ ID NO: 21 and 13, SEQ ID NO: 14 and 8, SEQ ID NO: 15 and 9, SEQ ID NO: 16 and 10, SEQ ID NO: 17 and 11, SEQ ID NO: 18 and 11, SEQ ID NO: 19 and 10, SEQ ID NO: 20 and 11, SEQ ID NO: 16 and 11, SEQ ID NO: 19 and 12, SEQ ID NO: 15 and 10.

### Claim 22 (depends on 21)

The compound of claim 21, wherein the antibody further comprises a Human IgG1 Constant heavy chain (CH) and/or a Human IgG1 Constant light chain (CL).

### Claim 23 (depends on 18)

The compound of claim 18, wherein the chelating moiety comprises NODAGA, NODAGA-NHS, DOTA, DOTA-NHS, p-SCN-Bn-NOTA, p-SCN-Bn-PCTA, p-SCN-Bn-oxo-DO3A, desferrioxamine-p-SCN, Diethylenetriamine Pentaacetic Acid (DTPA), or 1,4,8,11-Tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA).

### Claim 24 (depends on 19)

The compound of claim 19, wherein the radioisotope is 68Ga, 64Cu, 89Zr, 186Re, 188Re, 153Sm, 111In, 99mTc, 123I, 177Lu, 90Y, 131I, 213Bi, 212Bi, 211At or 225Ac.

### Claim 25

A method for imaging Netrin-1 presence or localization in a subject, comprising:
a) administering to said subject a compound comprising:
an anti-Netrin-1 antibody or antigen binding fragment thereof,
a chelating moiety bound to said antibody or fragment, and
a radioisotope associated to the chelating moiety,
b) waiting from 4 to 172 h, obtaining binding of said compound by the netrin-1 sequestered in the extracellular matrix of the tumor;
c) detecting or localizing said bound compound by in vivo imaging.

### Claim 26 (depends on 25)

The method of claim 25, wherein localizing at step b) comprises highlighting the presence or accumulation of the compound in at least one body part.

### Claim 27 (depends on 26)

The method of claim 26, wherein said body part is an organ or a tissue.

### Claim 28 (depends on 25)

The method of claim 25, wherein the radioisotope is selected from the group consisting of 68Ga, 64Cu, 89Zr, 186Re, 188Re, 153Sm, 111In, 99mTc, and 123I.

### Claim 29

A method of internal radiotherapy treatment of a netrin-1 expressing cancer in a patient having such cancer, comprising administering a sufficient amount of a compound comprising:
an anti-Netrin-1 antibody or antigen binding fragment thereof,
a chelating moiety bound to said antibody or fragment, and
a radioisotope associated to the chelating moiety.

### Claim 30 (depends on 29)

The method of claim 29, wherein the compound comprises a radioisotope selected from the group consisting of 177Lu, 90Y, 131I, 213Bi, 212Bi, 211At and 225Ac.

### Claim 31

A method of identifying and treating patients with a netrin-1 expressing cancer, comprising:
a) administering to said subject a compound comprising:
an anti-Netrin-1 antibody or antigen binding fragment thereof,
a chelating moiety bound to said antibody or fragment, and
a radioisotope associated to the chelating moiety;
b) waiting from 4 to 172 h, obtaining binding of said compound by the netrin-1 sequestered in the extracellular matrix of the tumor;
c) detecting said compound by in vivo imaging;
d) visualizing localization of Netrin-1 presence or accumulation;
e) treating said patient against the visualized cancer.

### Claim 32 (depends on 31)

The method of claim 31 wherein the compound in a) comprises a radioisotope selected from the group consisting of 68Ga, 64Cu, 89Zr, 186Re, 188Re, 153Sm, 111In, 99mTc, and 123I.

### Claim 33 (depends on 31)

The method of claim 31, wherein treating the patient in e) comprises administering to said patient an effective amount of a compound comprising:
an anti-Netrin-1 antibody or antigen binding fragment thereof,
a chelating moiety bound to said antibody or fragment, and
a radioisotope associated to the chelating, wherein the radioisotope is selected from the group consisting of 177Lu, 90Y, 131I, 213Bi, 212Bi, 211At and 225Ac.

### Claim 34 (depends on 31)

The method of claim 31, wherein treating the patient in e) comprises administering to said patient an effective amount of a monoclonal antibody or an antigen-binding fragment thereof, comprising
a variable domain VH comprising:
a H-CDR1 having a sequence set forth as SEQ ID NO: 1;
a H-CDR2 having a sequence set forth as SEQ ID NO: 2;
a H-CDR3 having a sequence set forth as SEQ ID NO: 3;
a variable domain VL comprising:
a L-CDR1 having a sequence set forth as SEQ ID NO: 4;
a L-CDR2 having a sequence YAS;
a L-CDR3 having a sequence set forth as SEQ ID NO: 5;
or
a variable domain VH comprising:
a H-CDR1 having a sequence set forth as SEQ ID NO: 22;
a H-CDR2 having a sequence set forth as SEQ ID NO: 23;
a H-CDR3 having a sequence set forth as SEQ ID NO: 24;
a variable domain VL comprising:
a L-CDR1 having a sequence set forth as SEQ ID NO: 25;
a L-CDR2 having a sequence set forth as SEQ ID NO: 26;
a L-CDR3 having a sequence set forth as SEQ ID NO: 5.

### Claim 35 (depends on 34)

The method of claim 34, wherein the antibody is a monoclonal antibody or an antigen-binding fragment thereof, wherein the antibody is a monoclonal antibody or an antigen-binding fragment thereof, comprising a pair of VH and VL sequences selected from the following pairs: SEQ ID NO: 21 and 13, SEQ ID NO: 14 and 8, SEQ ID NO: 15 and 9, SEQ ID NO: 16 and 10, SEQ ID NO: 17 and 11, SEQ ID NO: 18 and 11, SEQ ID NO: 19 and 10, SEQ ID NO: 20 and 11, SEQ ID NO: 16 and 11, SEQ ID NO: 19 and 12, SEQ ID NO: 15 and 10.

### Claim 36 (depends on 31)

The method of claim 31, wherein in vivo imaging comprises PET or SPECT imaging.

### Claim 37

A compound comprising:
an anti-Netrin-1 antibody or antigen binding fragment thereof, and
a chelating moiety bound to said antibody or fragment.
wherein said chelating moiety is optionally associated with a radioisotope and wherein the antibody is a monoclonal antibody or an antigen-binding fragment thereof, comprising
a variable domain VH comprising:
a H-CDR1 having a sequence set forth as SEQ ID NO: 1;
a H-CDR2 having a sequence set forth as SEQ ID NO: 2;
a H-CDR3 having a sequence set forth as SEQ ID NO: 3;
a variable domain VL comprising:
a L-CDR1 having a sequence set forth as SEQ ID NO: 4;
a L-CDR2 having a sequence YAS;
a L-CDR3 having a sequence set forth as SEQ ID NO: 5;
or
a variable domain VH comprising:
a H-CDR1 having a sequence set forth as SEQ ID NO: 22;
a H-CDR2 having a sequence set forth as SEQ ID NO: 23;
a H-CDR3 having a sequence set forth as SEQ ID NO: 24;
a variable domain VL comprising:
a L-CDR1 having a sequence set forth as SEQ ID NO: 25;
a L-CDR2 having a sequence set forth as SEQ ID NO: 26;
a L-CDR3 having a sequence set forth as SEQ ID NO: 5.
